Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients

Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients

Abstract Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission. These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of care and increased mortality. Social isolation str...

Full description

Bibliographic Details
Main Authors: Irma Convertino, Marco Tuccori, Sara Ferraro, Giulia Valdiserra, Emiliano Cappello, Daniele Focosi, Corrado Blandizzi
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Critical Care
Subjects:
Sars-CoV-2
COVID-19
Cytokines
Interleukin-6
Tumor necrosis factor
Janus kinases
Online Access:http://link.springer.com/article/10.1186/s13054-020-03020-3
Description
Summary:Abstract Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission. These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of care and increased mortality. Social isolation strategies have been implemented worldwide with the aim of reducing hospital pressure. Among therapeutic strategies, the use of immunomodulating drugs, to improve prognosis, seems promising. Particularly, since pneumonia and ARDS are associated with a cytokine storm, drugs belonging to therapeutic classes as anti-IL-6, anti-TNF, and JAK inhibitors are currently studied. In this article, we discuss the potential advantages of the most promising pharmacological approaches.
ISSN:1364-8535

Similar Items